Psoriatic arthritis
Adela Castro AdelaCastro222
10 months 3 weeks ago
🚨Therapeutic target in PsO?
Abst#0067 from Cleveland Clinic evaluated pts w/ PsO at high risk for PsA (HR-PsO).
- HR-PsO: ⬆️percentage in migratory dendritic cells with elevated expression of CXCR4.
- Migratory effect ⬇️ after selective CXCR4 inhibitor. #ACR24 @ElaineHusniMD… https://t.co/nVoAThUxi1 https://t.co/8d1K3nkttI
Adela Castro AdelaCastro222
10 months 3 weeks ago
🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure:
-Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie
#ACR24 @RheumNow https://t.co/Jc0cdmrVhI
Akhil Sood MD AkhilSoodMD
10 months 3 weeks ago
Abstract 0587: Among PsA patients (bDMARD-naive & TNF non-responders) treated with Bimekizumab, better disease control was linked to improved work productivity, including ↓ work impairment, ↓ presenteeism, and ↓ activity impairment. #ACR24 @RheumNow https://t.co/sZBjJ9lk39
Adela Castro AdelaCastro222
10 months 3 weeks ago
High PBO effect in PsA studies
Abst#0772 from U. of Vienna analyzed PBO arms of PsA trials for bDMARDs and tsDMARDs on ACR response rates at week 12:
💡PBO rates significantly increased over time.
💡Recruitment patterns increasing in geographic areas with less affluent health… https://t.co/wAJnwjYkVe
Caoilfhionn Connolly CaoilfhionnMD
10 months 3 weeks ago
#0582🔬Challenges in Achieving PsA Disease Control
➡️n=2,093; 18% and 8% achieved minimal, very low disease activity respectively
🔑Higher QoL & monotherapy⬆️success; female sex, fatigue, spine pain⬇️outcomes.
🩺Unmet needs remain in PsA; tailored Rx needed
#ACR24 @RheumNow
Antoni Chan MD (Prof) synovialjoints
10 months 3 weeks ago
The rising placebo response rates in PsA trials are linked to global recruiting patterns, with more studies in less affluent countries. Limited access to healthcare may drive this trend, highlighting the need for awareness among stakeholders. Plenary Abstr#0722… https://t.co/FplpSlIamR https://t.co/NIp76IS6TZ
Richard Conway RichardPAConway
10 months 3 weeks ago
Kerschbaumer et al. Rising placebo rates in PsA RCTs appear linked to changes in global recruitment patterns. Dramatic relationship between GNI and placebo response rate. Crucial information for properly planning future trials @RheumNow #ACR24 Abstr#0772 https://t.co/PtHs2RXe0f https://t.co/OKG6czQrYD
Eric Dein ericdeinmd
10 months 3 weeks ago
Location of research matters Ab#0772
Global recruiting patterns impact PBO in PsA
PBO results improve w time - 0.9%/year
More globalization of trials w time
Gross nation index (GNI) neg ass w ACR20 - inclusion of less affluent controls affects higher PBO response
@RheumNow #ACR24
sheila RHEUMarampa
10 months 3 weeks ago
TNFi cycling vs. switching to IL-17Ai?
Dr @AlexisOgdie et al from CorEvitas registry:
PsA & axSpA cohort - switchers (TNFi to IL17i) had greater improvements in cDAPSA & BASDAI vs. cyclers (2nd TNF)
Not stat significant but offers alternative Tx options
@RheumNow #ACR24 abs585 https://t.co/8m347BRM75
Antoni Chan MD (Prof) synovialjoints
10 months 3 weeks ago
Dr. Catherine Bakewell @CatherineB27 shares the preliminary ACR guidelines on ultrasound imaging in psoriatic arthritis covering 4 domains, detailed PICOs covering the early phase, diagnosis, assessment covering the domains of PsA @RheumNow #ACR24 https://t.co/DoHE1rsSGf
Adela Castro AdelaCastro222
10 months 3 weeks ago
Dactylitis management in PsA:
Acute: pain and swelling
Chronic: painless swelling
Broad ddx
No role for LEF or SSZ
#ReviewCourse #ACR24 @RheumNow https://t.co/KZXv1UvhXn
Adela Castro AdelaCastro222
10 months 3 weeks ago
Great summary of treatment choices in PsA:
1. Identify domain involved
2. Identify comorbidities/pt preferences
3. Still unmet needs for ttx in inflammatory eye disease
#ACR24 @rheumnow https://t.co/1WMnkDYvip
Patricia Harkins DrTrishHarkins
10 months 3 weeks ago
Amazing review @NamrataRheum on the important role the rheumatologist can play to improve the care of our older patients!
Don’t forget the 5Ms!
🧠Mind (cog/mood)
💊Medication (PIM)
🏃♀️Mobility
👉Multi-complexity
💪🏻Matters most (pt priority)
@RheumNow #ACR24 #gerirheum https://t.co/0Iv4TdS8AX
Unlike traditional imaging techniques, MSUS can be easily used at the point-of-care and offers high-resolution images of joints, tendons, and soft tissues, facilitating the early detection of inflammation and structural damage. On Saturday, November 16th at the ACR Convergence 2024, Dr. Veena Ranganath, Dr. Gurjit Kaeley, and Dr. Catherine Bakewell will present the “Proposed ACR Guidance for Use of Musculoskeletal Ultrasound in Rheumatoid and
ACR24 Begins today. Many of the great presentations for this meeting come from industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
Poster Hall